Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 16, 2011

View Archived Issues

Novel histamine H4 receptor antagonist shows anti-inflammatory activity in vivo

FX-06 may be beneficial for renal transplant

Novo Nordisk reviews events of third quarter 2011

ProFibrix's phase II trial of Fibrocaps meets primary endpoint

AMG-145 assessed in first-in-human trial

Phase II results reported for miravirsen

PBI-4050 demonstrates nephroprotection in animal models

Chemokine as proinflammatory signal after traumatic brain injury

BIIB-023 demonstrates favorable safety and tolerability profile in rheumatoid arthritis trial

Korean scientists patent new serotonin 5-HT4 receptor agonists

Novel haspin inhibitors designed by Brigham & Women's Hospital

GSK discloses novel macrolides for inflammatory disorders

New GPR119 agonists/DPP IV inhibitors claimed

Researchers at Roche prepare new HSL inhibitors

Probiodrug's PQ-912 shows promising topline phase I results

Geron discontinues stem cell programs

TGase-2 correlated with reduced survival in lung cancer

Fujifilm and Kyowa Hakko Kirin reach agreement on biosimilars

Promising results emerge from phase I/IIa Glymera study

Takeda begins phase II TAK-361S vaccine trials in Japan

The TB Alliance and U.S. NIAID join forces to accelerate REMox TB study

ViroPharma acquires DuoCort Pharma

Almirall and Forest Labs initiate phase III program for aclidinium/formoterol combination

SymBio announces plan for new study of SyB L-0501 in multiple myeloma

Menarini to expand presence in Asia-Pacific with acquisition of Invida

AMT's gene therapy for hemophilia B given orphan drug status in Europe

European Commission approves Vectibix for expanded indications

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.